Dosage & Administration Drug label Prior authorization Financial assistance

Skyrizi

(risankizumab)

0.83 ML risankizumab-rzaa 90.4 MG/ML Prefilled Syringe [Skyrizi]1 ML risankizumab-rzaa 150 MG/ML Auto-Injector [Skyrizi]

View 4 more

NO BLACK BOX WARNING

Dosage & administration

Recommended Dosage

Plaque Psoriasis and Psoriatic Arthritis:

* 150 mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.

* In patients with psoriatic arthritis SKYRIZI can be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs).

Crohn’s Disease:

* Obtain liver enzymes and bilirubin levels prior to initiating treatment with SKYRIZI.

* The recommended induction dosage is 600 mg administered by intravenous infusion over at least one hour at Week 0, Week 4, and Week 8. The recommended maintenance dosage is 180 mg or 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter. Use the lowest effective dosage to maintain therapeutic response.

Skyrizi prescribing information

Have more Skyrizi questions?

Submit MSL Request

Learn More

Need to report a Skyrizi issue?

ONLINE FORMReport adverse event

Learn More

prior authorization

Skyrizi Prior authorization resources

NOT PROVIDED BY BRANDComplete Letter of Medical Necessity

NOT PROVIDED BY BRANDComplete Coverage Authorization request

NOT PROVIDED BY BRANDComplete Coverage Authorization appeals

Coverage Authorization Request - Rheumatology

Coverage Authorization Appeal - Rheumatology

Letter of Medical Necessity - Rheumatology

Coverage Authorization Request - Dermatology

Coverage Authorization Appeal - Dermatology

Letter of Medical Necessity - Dermatology

Coverage Authorization Request - Gastroenterology

Learn More

Benefits investigation

Enrollment Form - Rheumatology & Dermatology

Enrollment Form - Gastroenterology

Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information

Learn More

financial assistance

Skyrizi Financial assistance options

Co-pay savings program

commercial only

Enroll in patient savings program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Enroll in Bridge Program

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Abbvie Patient Assistance Program Application - English

Abbvie Patient Assistance Program Application - Spanish

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement